Maintenance Immunosuppression in Severe Takayasu Arteritis
Initial Assessment and Treatment
- The American College of Rheumatology and Vasculitis Foundation guidelines recommend that patients with active Takayasu arteritis receive non-glucocorticoid immunosuppressive agents plus glucocorticoids, not glucocorticoids alone, for initial treatment and maintenance phases 2, 5, 6
- The European League Against Rheumatism guidelines state that non-biologic disease-modifying agents should be given in combination with glucocorticoids in all patients with Takayasu arteritis 1
- Patients with severe Takayasu arteritis, such as those with dilated cardiomyopathy and chronic kidney disease, require aggressive initial therapy with glucocorticoids plus non-glucocorticoid immunosuppression 1, 2
Maintenance Therapy
- The American College of Rheumatology recommends transitioning to another non-glucocorticoid immunosuppressive agent, such as methotrexate or azathioprine, after cyclophosphamide induction therapy 4
- Maintenance immunosuppression should continue for at least 18 months after achieving remission, and some patients may require indefinite maintenance therapy 4
- The European League Against Rheumatism guidelines recommend that patients with severe Takayasu arteritis receive maintenance immunosuppressive therapy to prevent relapse and disease progression 1
Biologic Therapy
- For relapsing or refractory disease despite conventional immunosuppressants, biologic agents such as TNF inhibitors or tocilizumab should be considered 2, 1
- Biologics can enable significant reduction in glucocorticoid dose and reduce relapse rates 2, 1
Glucocorticoid Management
- After achieving remission for ≥6-12 months, glucocorticoids can be tapered off rather than maintained long-term, with a target dose of ≤10 mg/day prednisolone 2, 5, 6
- The American College of Rheumatology recommends tapering glucocorticoids slowly, with a feasible maintenance dose of 5 mg/day or less, especially when biologics are used 1